A review of recent advancements in Actinium‐225 labeled compounds and biomolecules for therapeutic purposes
暂无分享,去创建一个
[1] L. Filippi,et al. The Role of PET and SPECT Imaging in Prostate Cancer Targeted Alpha Therapy: When and How? , 2023, Applied Sciences.
[2] T. Stora,et al. Resonant laser ionization and mass separation of 225Ac , 2023, Scientific Reports.
[3] James Jin Kang,et al. Nafion Modified Titanium Nitride pH Sensor for Future Biomedical Applications , 2023, Sensors.
[4] T. Parac‐Vogt,et al. Inorganic Radiolabeled Nanomaterials in Cancer Therapy: A Review , 2022, ACS Applied Nano Materials.
[5] Justin J. Wilson,et al. H2BZmacropa-NCS: A Bifunctional Chelator for Actinium-225 Targeted Alpha Therapy. , 2022, Bioconjugate chemistry.
[6] F. Mottaghy,et al. Radiolabeled Nanocarriers as Theranostics-Advancement from Peptides to Nanocarriers. , 2022, Small.
[7] James M. Kelly,et al. A suitable time point for quantifying the radiochemical purity of 225Ac-labeled radiopharmaceuticals , 2021, EJNMMI Radiopharmacy and Chemistry.
[8] Sukhvir Singh,et al. Recent Advances in Brachytherapy Using Radioactive Nanoparticles: An Alternative to Seed-Based Brachytherapy , 2021, Frontiers in Oncology.
[9] Justin J. Wilson,et al. Harnessing α-Emitting Radionuclides for Therapy: Radiolabeling Method Review , 2021, The Journal of Nuclear Medicine.
[10] M. Ono,et al. Radiotheranostics Using a Novel 225Ac-Labeled Radioligand with Improved Pharmacokinetics Targeting Prostate-Specific Membrane Antigen. , 2021, Journal of medicinal chemistry.
[11] M. Piert,et al. Synthesis of 225Ac-PSMA-617 for preclinical use. , 2021, Current Radiopharmaceuticals.
[12] Mingyuan Gao,et al. A Pretargeting Strategy Enabled by Bioorthogonal Reactions Towards Advanced Nuclear Medicines: Application and Perspective , 2021, Chemical Research in Chinese Universities.
[13] F. Haddad,et al. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight” , 2021, Pharmaceutics.
[14] Y. Seimbille,et al. Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC , 2021, Pharmaceutics.
[15] K. Kopka,et al. Towards Targeted Alpha Therapy with Actinium-225: Chelators for Mild Condition Radiolabeling and Targeting PSMA—A Proof of Concept Study , 2021, Cancers.
[16] R. Engelman,et al. Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms , 2021, European Journal of Nuclear Medicine and Molecular Imaging.
[17] B. Mittal,et al. Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis , 2021, Prostate Cancer and Prostatic Diseases.
[18] G. Ossenkoppele,et al. Two decades of targeted therapies in acute myeloid leukemia , 2021, Leukemia.
[19] N. Callander,et al. Targeted treatment of multiple myeloma with a radioiodinated small molecule radiopharmaceutical , 2021, Leukemia & lymphoma.
[20] S. Graves,et al. Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy. , 2021, Seminars in radiation oncology.
[21] F. Wuest,et al. Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications , 2020, Pharmaceutics.
[22] P. Choyke,et al. Glypican-3-Targeted Alpha Particle Therapy for Hepatocellular Carcinoma , 2020, Molecules.
[23] D. Ludwig,et al. 225Ac‐labeled CD33‐targeting antibody reverses resistance to Bcl‐2 inhibitor venetoclax in acute myeloid leukemia models , 2020, Cancer medicine.
[24] A. Vasiliev,et al. Radiation Stability of Sorbents in Medical 225Ac/213Bi Generators , 2020 .
[25] S. Frank,et al. Evaluation of Actinium-225 Labeled Minigastrin Analogue [225Ac]Ac-DOTA-PP-F11N for Targeted Alpha Particle Therapy , 2020, Pharmaceutics.
[26] J. Falandysz,et al. A Review of the Occurrence of Alpha-Emitting Radionuclides in Wild Mushrooms , 2020, International journal of environmental research and public health.
[27] A. Colao,et al. Advances in the Management of Medullary Thyroid Carcinoma: Focus on Peptide Receptor Radionuclide Therapy , 2020, Journal of clinical medicine.
[28] S. Gauny,et al. Evaluating 225Ac and 177Lu Radioimmunoconjugates against Antibody-Drug Conjugates for Small-Cell Lung Cancer. , 2020, Molecular pharmaceutics.
[29] G. Böning,et al. Response to 225Ac-PSMA-I&T after failure of long-term 177Lu-PSMA RLT in mCRPC , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[30] S. Larson,et al. Alpha radioimmunotherapy using 225Ac-proteus-DOTA for solid tumors - safety at curative doses , 2020, Theranostics.
[31] Mohammed Z. Rahman,et al. Alpha emitting nuclides for targeted therapy. , 2020, Nuclear medicine and biology.
[32] J. Bading,et al. Preclinical PET Imaging of NTSR-1-Positive Tumors with 64Cu- and 68Ga-DOTA-Neurotensin Analogs and Therapy with an 225Ac-DOTA-Neurotensin Analog. , 2020, Cancer biotherapy & radiopharmaceuticals.
[33] Angel Cortez,et al. Evaluation of [225Ac]Ac-DOTA-anti-VLA-4 for targeted alpha therapy of metastatic melanoma. , 2020, Nuclear medicine and biology.
[34] E. Oosterwijk,et al. Therapeutic efficacy and tolerability of [225Ac]Ac-DOTA-hG250 targeted alpha therapy in a clear cell renal cell carcinoma mice model , 2020 .
[35] F. Bénard,et al. Synthesis and Evaluation of a New Macrocyclic Actinium-225 Chelator, Quality Control and in Vivo Evaluation of 225Ac-crown-αMSH Peptide. , 2020, Chemistry.
[36] S. McMahon,et al. Targeted Alpha Therapy: Current Clinical Applications. , 2020, Cancer biotherapy & radiopharmaceuticals.
[37] P. Causey,et al. Construction of a thorium/actinium generator at the Canadian Nuclear Laboratories. , 2020, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[38] S. Larson,et al. Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted α-particle therapy , 2020, Proceedings of the National Academy of Sciences.
[39] P. Mukherjee,et al. Preclinical evaluation of an 111In/225Ac theranostic targeting transformed MUC1 for triple negative breast cancer , 2020, Theranostics.
[40] R. Vessella,et al. Evaluation of radioiodinated protein conjugates and their potential metabolites containing lysine-urea-glutamate (LuG), PEG and closo-decaborate(2-) as models for targeting astatine-211 to metastatic prostate cancer. , 2020, Nuclear medicine and biology.
[41] F. Bénard,et al. 225Ac-H4py4pa for Targeted-Alpha-Therapy. , 2020, Bioconjugate chemistry.
[42] E. Demirci,et al. Post-therapy imaging of 225Ac-DOTATATE treatment in a patient with recurrent neuroendocrine tumor , 2020, European Journal of Nuclear Medicine and Molecular Imaging.
[43] C. Apostolidis,et al. Supply and Clinical Application of Actinium-225 and Bismuth-213 , 2020, Seminars in nuclear medicine.
[44] M. de Jong,et al. Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward , 2020, Current topics in medicinal chemistry.
[45] U. Haberkorn,et al. 225Ac-PSMA-617 for Therapy of Prostate Cancer. , 2020, Seminars in nuclear medicine.
[46] R. Bazzi,et al. A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225 , 2020, Pharmaceutics.
[47] S. Fawcus,et al. Antenatal blood transfusion in South Africa: indications and practice in a high‐HIV‐prevalence setting , 2020, Transfusion.
[48] D. Kusewitt,et al. Pre-Clinical Evaluation of 225Ac-DOTATOC Pharmacokinetics, Dosimetry, and istopathology to Enable Phase-1 Clinical Trial in Patients with Neuroendocrine Tumors , 2019, Journal of Medical Imaging and Radiation Sciences.
[49] R. Sahoo,et al. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[50] V. Solomon,et al. 111In and 225Ac-labeled cixutumumab for imaging and alpha particle radiotherapy of IGF-1R positive triple negative breast cancer. , 2019, Molecular pharmaceutics.
[51] G. Bormans,et al. Design and Challenges of Radiopharmaceuticals. , 2019, Seminars in nuclear medicine.
[52] C. Parker,et al. Advances in targeted alpha therapy for prostate cancer , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[53] A. Denkova,et al. The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier , 2019, Scientific Reports.
[54] F. Bénard,et al. Evaluation of polydentate picolinic acid chelating ligands and an α-melanocyte-stimulating hormone derivative for targeted alpha therapy using ISOL-produced 225Ac , 2019, EJNMMI Radiopharmacy and Chemistry.
[55] E. Moros,et al. Lipophilicity Determines Route of Clearance of a Melanocortin 1 Receptor Targeted Radiopharmaceutical , 2019 .
[56] A. Denkova,et al. Therapeutic Efficacy of 225Ac-containing Polymersomes , 2019, Journal of Medical Imaging and Radiation Sciences.
[57] F. Bénard,et al. Bench to Bedside: Albumin Binders for Improved Cancer Radioligand Therapies. , 2019, Bioconjugate chemistry.
[58] James M. Kelly,et al. A Single Dose of 225Ac-RPS-074 Induces a Complete Tumor Response in an LNCaP Xenograft Model , 2018, The Journal of Nuclear Medicine.
[59] J. Harvey. NorthStar Perspectives for Actinium-225 Production at Commercial Scale. , 2018, Current radiopharmaceuticals.
[60] Paul Schaffer,et al. Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences , 2018, Current radiopharmaceuticals.
[61] J. Engle. The Production of Ac-225. , 2018, Current radiopharmaceuticals.
[62] Justin J. Wilson,et al. Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches. , 2018, Cancer biotherapy & radiopharmaceuticals.
[63] U. Haberkorn,et al. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[64] E. Boros,et al. Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers. , 2018, Journal of labelled compounds & radiopharmaceuticals.
[65] L. Królicki,et al. In vitro evaluation of 225Ac‐DOTA‐substance P for targeted alpha therapy of glioblastoma multiforme , 2018, Chemical biology & drug design.
[66] P. Sminia,et al. The therapeutic potential of polymersomes loaded with 225Ac evaluated in 2D and 3D in vitro glioma models , 2018, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[67] S. Larson,et al. Pretargeted radioimmunotherapy with 225Ac-proteus-DOTA hapten. , 2018 .
[68] M. Miederer,et al. In vivo Evaluation of [225Ac]Ac-DOTAZOL for α-Therapy of Bone Metastases. , 2018, Current radiopharmaceuticals.
[69] S. Larson,et al. Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer , 2018, Nature Communications.
[70] T. Lahoutte,et al. Evaluation of an Anti-HER2 Nanobody Labeled with 225Ac for Targeted α-Particle Therapy of Cancer. , 2018, Molecular pharmaceutics.
[71] S. Larson,et al. I-124 codrituzumab imaging and biodistribution in patients with hepatocellular carcinoma , 2018, EJNMMI Research.
[72] James M. Kelly,et al. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of 68Ga3+, 111In3+, 177Lu3+ and 225Ac3. , 2017, Nuclear medicine and biology.
[73] James M. Kelly,et al. An Eighteen-Membered Macrocyclic Ligand for Actinium-225 Targeted Alpha Therapy. , 2017, Angewandte Chemie.
[74] C. Steer,et al. Global geriatric oncology: Achievements and challenges. , 2017, Journal of geriatric oncology.
[75] O. Artun. Estimation of the production of medical Ac-225 on thorium material via proton accelerator. , 2017, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[76] C. Brayton,et al. Pharmacokinetics, microscale distribution, and dosimetry of alpha-emitter-labeled anti-PD-L1 antibodies in an immune competent transgenic breast cancer model , 2017, EJNMMI Research.
[77] A. Mintz,et al. IL13RA2 targeted alpha particle therapy against glioblastomas , 2017, Oncotarget.
[78] King Li,et al. Preliminary Therapy Evaluation of 225Ac-DOTA-c(RGDyK) Demonstrates that Cerenkov Radiation Derived from 225Ac Daughter Decay Can Be Detected by Optical Imaging for In Vivo Tumor Visualization , 2016, Theranostics.
[79] E. Estey,et al. Phase I trial of {alpha}-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML. , 2015 .
[80] S. Larson,et al. Targeted alpha-particle therapy of disseminated prostate cancer with 225-Actinium-11B6 , 2015 .
[81] D. Scheinberg,et al. Encapsulation of α-Particle–Emitting 225Ac3+ Ions Within Carbon Nanotubes , 2015, The Journal of Nuclear Medicine.
[82] D. Scheinberg,et al. Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with 225Ac for α-Particle Radioimmunotherapy of Cancer , 2014, The Journal of Nuclear Medicine.
[83] A. Mintz,et al. Radiochemistry and biological evaluation of 225Ac-DOTA-c(RGDyK), a potential radiopharmaceutical for targeted alpha particle therapy , 2014 .
[84] B. Kaina,et al. DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy , 2014, PloS one.
[85] M. A. Motaleb,et al. Preparation, molecular modeling and biodistribution of 99mTc-phytochlorin complex , 2014, Journal of Radioanalytical and Nuclear Chemistry.
[86] C. Orvig,et al. Tumour targeting with radiometals for diagnosis and therapy. , 2013, Chemical communications.
[87] Young-Seung Kim,et al. An overview of targeted alpha therapy , 2012, Tumor Biology.
[88] U. Haberkorn,et al. Bifunctional chelators in the design and application of radiopharmaceuticals for oncological diseases. , 2012, Current medicinal chemistry.
[89] R. Senekowitsch-Schmidtke,et al. Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[90] David A Scheinberg,et al. Actinium-225 in targeted alpha-particle therapeutic applications. , 2011, Current radiopharmaceuticals.
[91] B. Allen,et al. Analysis of patient survival in a Phase I trial of systemic targeted α-therapy for metastatic melanoma. , 2011, Immunotherapy.
[92] E. Giné,et al. Current immunochemotherapy strategies in follicular lymphoma , 2010, Advances in therapy.
[93] B. Wessels,et al. MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy* , 2010, Journal of Nuclear Medicine.
[94] D. Scheinberg,et al. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. , 2008, Advanced drug delivery reviews.
[95] Pius August Schubiger,et al. Molecular imaging with PET. , 2008, Chemical reviews.
[96] E. Medine,et al. 99mTc-glucoheptonate-guanine: Synthesis, biodistribution and imaging in animals , 2008 .
[97] M. Brechbiel. Targeted α-therapy: past, present, future? , 2007 .
[98] J. Fitzsimmons,et al. Synthesis and evaluation of a water-soluble polymer to reduce Ac-225 daughter migration , 2007 .
[99] G. Griffiths,et al. Cancer Therapy with Radiolabeled and Drug/Toxin-conjugated Antibodies , 2005, Technology in cancer research & treatment.
[100] S. Mirzadeh,et al. Production of actinium-225 for alpha particle mediated radioimmunotherapy. , 2005, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.
[101] O. Couturier,et al. Cancer radioimmunotherapy with alpha-emitting nuclides , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[102] D. Scheinberg,et al. Targeted deletion of T-cell clones using alpha-emitting suicide MHC tetramers. , 2004, Blood.
[103] S. Kennel,et al. Actinium-225 Conjugates of MAb CC49 and Humanized ΔCH2CC49 , 2002 .
[104] L. Chappell,et al. Synthesis, conjugation, and radiolabeling of a novel bifunctional chelating agent for (225)Ac radioimmunotherapy applications. , 2000, Bioconjugate chemistry.
[105] S. Kennel,et al. Evaluation of 225Ac for vascular targeted radioimmunotherapy of lung tumors. , 2000, Cancer biotherapy & radiopharmaceuticals.
[106] J. Humm,et al. Radioimmunotherapy with alpha-emitting nuclides , 1998, European Journal of Nuclear Medicine.
[107] B. Mittal,et al. Orbital and brain metastases on 68Ga-PSMA PET/CT in a patient with prostate carcinoma refractory to 177Lu-PSMA and 225Ac-PSMA therapy. , 2021, Asia Oceania journal of nuclear medicine & biology.
[108] Ashutosh Dash,et al. Introduction: Radiopharmaceuticals Play an Important Role in Both Diagnostic and Therapeutic Nuclear Medicine , 2016 .
[109] S. Adelstein,et al. Radiobiologic principles in radionuclide therapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[110] D. Scheinberg,et al. The promise of targeted {alpha}-particle therapy. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.